Day: Nov 27, 2019

Cardiology, Endocrinology

#Dapagliflozin in Patients with Heart Failure and Reduced #Ejection Fraction

In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms.. A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard ratio, 0.70; 95% CI, 0.59 to 0.83). Death from cardiovascular causes occurred in 227 … Continue reading #Dapagliflozin in Patients with Heart Failure and Reduced #Ejection Fraction

aledopress
Cardiology, Endocrinology, Hypertension

Altered Risk for #cardiovascular Events With Changes in the #Metabolic Syndrome Status: A Nationwide Population-Based Study of Approximately 10 Million Persons

Population-scale evidence for the association between dynamic changes in metabolic syndrome (MetS) status and alterations in the risk for major adverse cardiovascular events (MACE) is lacking ..At a median follow-up of 3.54 years, the MetS-recovery group (incidence rate, 4.55 per 1000 person-years) had a significantly lower MACE risk (adjusted IRR, 0.85 [95% CI, 0.83 to 0.87]) than that of the MetS-chronic group (incidence rate, 8.52 … Continue reading Altered Risk for #cardiovascular Events With Changes in the #Metabolic Syndrome Status: A Nationwide Population-Based Study of Approximately 10 Million Persons

aledopress